Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUAVEE vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis
Moderate to severe pain where an opioid analgesic is appropriate
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Conjugated estrogens are primarily metabolized in the liver via phase II conjugation (sulfation and glucuronidation) by enzymes such as UGT1A1, UGT1A8, UGT1A9, UGT2B7, and SULT1A1. Bazedoxifene undergoes hepatic metabolism via glucuronidation by UGT1A1, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP involvement.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Conjugated estrogens: extensive binding to albumin (approximately 80-85%). Bazedoxifene: highly bound (>99%) to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Conjugated estrogens: Vd approximately 0.5-2 L/kg, indicating distribution into total body water and tissues. Bazedoxifene: Vd approximately 1.2 L/kg, suggesting extensive tissue distribution.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Conjugated estrogens: oral bioavailability is approximately 30-50% due to first-pass metabolism. Bazedoxifene: absolute oral bioavailability is approximately 6% due to extensive first-pass glucuronidation.
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh Class A or B; no specific dose adjustment established, but monitor closely.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Not indicated for use in pediatric patients. Safety and efficacy have not been established.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
No specific dose adjustment recommended. Higher risk of adverse events (e.g., thromboembolism, stroke) in women >65 years of age; use lowest effective dose for shortest duration.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
Estrogen therapy increases the risk of endometrial cancer in women with a uterus. Concomitant use of a progestin or bazedoxifene is required to reduce this risk. Cardiovascular disorders: Estrogen-alone therapy may increase risk of stroke and DVT. Estrogen plus progestin therapy increases risk of MI, stroke, invasive breast cancer, pulmonary emboli, and DVT. DUAVEE is not approved for cardiovascular disease prevention. Breast cancer: Estrogen plus progestin therapy increases risk of invasive breast cancer. Probable dementia: Estrogen plus progestin therapy increases risk in women 65+.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Cardiovascular disorders (stroke, DVT, MI, pulmonary embolism),Malignant neoplasms (endometrial cancer, breast cancer),Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Exacerbation of asthma, diabetes, migraine, porphyria, SLE, hepatic hemangiomas,Retinal vascular thrombosis
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE),Active or past history of arterial thromboembolism (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hypersensitivity to any component,Pregnancy
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Grapefruit juice may increase estrogen levels; avoid large amounts. No other significant food interactions. Alcohol may increase risk of liver issues; limit intake.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and delayed cognitive development. Bazedoxifene is a selective estrogen receptor modulator; animal studies show embryotoxicity and fetotoxicity at clinically relevant doses.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Contraindicated during breastfeeding. Estrogens and bazedoxifene are excreted in human milk; M/P ratio not reported. Estrogens may reduce milk production and quality. Potential for adverse effects in nursing infants.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
No dose adjustments applicable; do not use in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
DUAVEE (conjugated estrogens/bazedoxifene) is indicated for moderate-to-severe vasomotor symptoms and osteoporosis prevention in postmenopausal women with a uterus. Avoid in women with intact uterus who are not on a progestin; bazedoxifene is the progestin component. Contraindicated in women with undiagnosed abnormal genital bleeding, known/suspected pregnancy, breast cancer, estrogen-dependent neoplasia, active DVT/PE, or history of these conditions. Monitor for thromboembolic events. Not for use in women with prior hysterectomy. Discontinue if jaundice or visual disturbances occur.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Take DUAVEE once daily with or without food.,This medication is for postmenopausal women with a uterus; it contains both estrogen and a progestin-like drug to protect the uterine lining.,Do not use if you have any unexplained vaginal bleeding, are pregnant, have or have had breast cancer, blood clots, or liver disease.,Report promptly any signs of blood clots (leg pain/swelling, chest pain, sudden shortness of breath) or stroke (sudden headache, vision/speech changes).,DUAVEE may increase risk of gallbladder disease, dementia (if started after age 65), and endometrial hyperplasia if the progestin component fails.,Smoking while on DUAVEE increases risk of blood clots; avoid smoking.,DUAVEE does not prevent heart attack or stroke; in fact, it may increase cardiovascular risk, especially in older women.,Store at room temperature, away from moisture and heat.,If you miss a dose, take it as soon as possible; if almost time for the next dose, skip the missed dose and resume regular schedule. Do not double dose.,You will need regular medical check-ups including mammograms and pelvic exams.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
No interactions on record
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUAVEE vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
DUAVEE is a Selective Estrogen Receptor Modulator/Estrogen Combination that works by DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUAVEE and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUAVEE is: One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUAVEE and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUAVEE is classified as Category C. DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies includi. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.